Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q1 2026 Earnings Call Transcript
TSHA - Taysha Gene Therapies, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$11.50
DETAILS
HIGH:
$13.00
LOW:
$11.00
MEDIAN:
$11.00
CONSENSUS:
$11.50
UPSIDE:
109.47%
Stock News
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, restricted stock units (RSUs) representing 188,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2026, and host a corporate update conference call and webcast on Wednesday, May 6, 2026, at 8:30 AM Eastern Time.
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 6.9% After Analyst Upgrade
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) were up 6.9% during mid-day trading on Monday after Canaccord Genuity Group raised their price target on the stock from $14.00 to $17.00. Canaccord Genuity Group currently has a buy rating on the stock. Taysha Gene Therapies traded as high as $4.64 and last
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA
Capricorn Fund Managers Ltd purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 300,000 shares of the company's stock, valued at approximately $1,650,000. Capricorn Fund Managers Ltd
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies Q4 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ: TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company's March 19 conference call. TSHA-102 development advances with FDA alignment and pivotal trial underway Chief Executive Officer
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Better-Than-Expected Earnings
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $4.45, but opened at $4.55. Taysha Gene Therapies shares last traded at $4.5150, with a volume of 715,255 shares traded. The company reported ($0.08) earnings per
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026
Ally Bridge Group NY LLC Acquires Shares of 1,898,112 Taysha Gene Therapies, Inc. $TSHA
Ally Bridge Group NY LLC acquired a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,898,112 shares of the company's stock, valued at approximately $6,207,000. Taysha Gene Therapies comprises 3.8% of Ally Bridge
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company's common stock and an option to purchase 134,460 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on February 2, 2026, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, restricted stock units (RSUs) representing 349,000 shares of the Company's common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of
Price Targets
Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated'
$13.00
(was $5.26)
Chris Raymond
·
Raymond James
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
$11.00
(was $5.25)
Zachary Fadem
·
Wells Fargo
Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs
$11.00
(was $4.49)
Goldman Sachs
Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy
$11.00
(was $4.49)
UBS
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA)
$13.00
(was $4.05)
Kristen Kluska
·
Cantor Fitzgerald
Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP
$8.00
(was $4.27)
JMP Securities
Taysha Gene Therapies price target raised to $12 from $7 at Baird
$12.00
(was $4.76)
Jack Allen
·
Robert W. Baird
Needham ups Taysha target on 'derisking' TSHA-102 news
$10.00
(was $4.76)
Gil Blum
·
Needham
BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA)
$5.00
(was $2.31)
Keith Tapper
·
BMO Capital
Taysha Gene Therapies (TSHA) PT Lowered to $7 at Piper Sandler
$7.00
(was $2.24)
Christopher Raymond
·
Piper Sandler
Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy
$8.00
(was $2.40)
Eun Yang
·
Jefferies
Piper Sandler Starts Taysha Gene Therapies (TSHA) at Overweight, 'Innovative Gene Therapy Story'
$9.00
(was $2.68)
Christopher Raymond
·
Raymond James
Jefferies Downgrades Taysha Gene Therapies to Hold, Lowers Price Target to $1.5
$1.50
(was $1.64)
Jefferies
Taysha Gene Therapies assumed with an Overweight at Morgan Stanley
$39.00
(was $17.63)
Matthew Harrison
·
Morgan Stanley
Taysha Gene Therapies initiated with an Overweight at Cantor Fitzgerald
$44.00
(was $21.78)
Kristen Kluska
·
Cantor Fitzgerald